logo
HomeResource

Does Parkinson's Disease Start in the Kidneys?| Alpha-Synuclein in PD

Written by Connor Wood
June 30, 2025

Does Parkinson's Disease Start in the Kidneys

For decades, Parkinson’s disease has been viewed as a brain-centered neurodegenerative disorder. But groundbreaking new research suggests a paradigm shift: ​Parkinson’s may begin in peripheral organs like the kidneys before reaching the brain​. Scientists have discovered abnormal accumulations of ​α-synuclein​—the hallmark protein of Parkinson’s—not only in the brain but also in kidney tissues.

This finding adds weight to a growing body of evidence linking ​renal dysfunction to Parkinson’s progression​. Chronic kidney problems may accelerate disease onset by promoting α-synuclein propagation and disrupting catecholamine excretion, affecting both neurological and renal functions. As research evolves, ​monitoring kidney health could become a crucial strategy for early detection and intervention in Parkinson’s disease​.

Check out this answer from PubMed.ai

For in-depth insights into the link between Parkinson’s disease and kidney health, download research reports directly from PubMed.ai to support your study or clinical decisions.

PubMed.ai Key Insights: Alpha-Synuclein and Parkinson's Disease

What is Alpha -Synuclein Protein?

Alpha-synuclein (α-Syn), a protein encoded by the SNCA gene, plays a crucial role in the pathogenesis of several neurodegenerative diseases, prominently including Parkinson's disease (PD). The aggregation of α-Syn is a hallmark of synucleinopathies, characterized by the accumulation of misfolded proteins that lead to neuronal dysfunction, inflammation, and eventual cell death. Recent research has explored various factors influencing α-Syn aggregation, including environmental toxins, genetic mutations, and circadian disruption. The increasing recognition of α-Syn's involvement in prodromal symptoms has highlighted the need for detailed insights into its role in neurodegeneration and potential therapeutic avenues. This review synthesizes current findings related to α-Syn, focusing on molecular mechanisms, pathological interactions, and diagnostic methods.

Connection Between Renal Function and Parkinson's Disease

  • Renal dysfunction can influence the incidence and severity of PD.
  • Chronic renal failure patients showed notable alpha-synuclein deposits in kidneys, potentially contributing to PD pathology.
  • Compromised kidney function might exacerbate PD symptoms by allowing neurotoxic substances to accumulate.

Neuroprotective Approaches

  • Vitamin E combined with levodopa/carbidopa shows significant neuroprotection in PD models.
  • Addresses oxidative stress and mitochondrial dysfunction linked to α-syn accumulation.

Environmental Triggers

  • Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) aggravates α-syn-mediated neurotoxicity.
  • Involves ferroptosis-related oxidative stress and neuroinflammation, suggesting environmental pollutants worsen PD pathology.

Circadian Disruption and Cognitive Impairment​

Genetic Mutations and α-Syn Pathology

  • G51D mutation in the SNCA gene disrupts α-syn localization, enhancing aggregation.
  • Highlights the genetic basis of α-synucleinopathies and their effects on disease progression.

Exploiting Post-Translational Modifications

  • Phosphorylated tau (p-tau) influences α-syn aggregation dynamics.
  • Trans isomers of p-tau enhance α-syn aggregation, illustrating complex interactions between misfolded proteins.

Advancements in Imaging Techniques

Therapeutic Potentials of Modulation

  • Modulating amyloid precursor protein (APP) processing with splice-switching antisense oligonucleotides reduces α-syn accumulation.
  • Suggests a therapeutic pathway targeting the interplay between amyloidogenic processes and α-syn pathology.

Conclusion - How does Alpha-Synuclein cause Parkinson's Disease？

Alpha-synuclein plays a crucial role in the pathogenesis of Parkinson's disease (PD), with misfolding and aggregation being key pathological hallmarks. Various studies highlight the neurotoxic mechanisms of alpha-synuclein, demonstrating its involvement in neuroinflammation, mitochondrial dysfunction, and interactions with environmental factors. Additionally, targeting alpha-synuclein through monoclonal antibodies presents a therapeutic avenue, although current clinical results remain inconclusive.

The ongoing research surrounding α-synuclein and its role in Parkinson's disease highlights the complexity of disease pathogenesis and the multifaceted therapeutic approaches necessary for effective management. Through advancements in neuroprotective strategies, biomarker discovery, genetic interventions, and imaging technologies, there is hope for improved outcomes in patients suffering from PD. Addressing environmental factors and exploring multi-target strategies will be crucial in the pursuit of successful treatments and, ultimately, a cure for this debilitating condition.

Whether you're a clinician, researcher, or student, staying ahead in Parkinson’s research means accessing the most up-to-date biomedical evidence. PubMed.ai's search engine empowers you to find relevant studies, track α-synuclein literature, and download structured research reports for quick synthesis. From early detection strategies to neuroprotective treatments, PubMed.ai offers AI-powered tools to support your clinical decisions and academic writing—all in one place.

If you want to read more, check out our other in-depth blogs:

Visit the PubMed.ai Blog for more insights into biomedical science, clinical research, and search optimization.

FAQ

How does Parkinson’s disease affect the kidneys?

Parkinson’s disease may impact kidney function through ​autonomic nervous system dysfunction, which can impair renal blood flow and alter filtration. Recent research also suggests that ​α-synuclein proteins​, known to accumulate in the brain, may also propagate from or to the kidneys, indicating a two-way connection between renal and neurological health. According to a study published on PubMed, this interplay may influence disease progression and patient outcomes.

Does Parkinson’s cause kidney problems?

While Parkinson’s disease does not directly cause kidney disease, it can contribute to ​urinary retention, incomplete bladder emptying, and increased infection risk​, which may place additional strain on the kidneys over time. Additionally, medications commonly used in Parkinson’s, such as anticholinergics, may have renal side effects.

How does Parkinson disease affect the urinary system?

Parkinson’s disease affects the ​autonomic nervous system​, which regulates bladder control. Many people with Parkinson’s experience symptoms like ​urgency, frequency, nocturia (nighttime urination), and incontinence. These issues stem from ​impaired signaling between the brain and bladder​. The National Institute of Neurological Disorders and Stroke (NINDS) notes that urinary dysfunction is one of the most common non-motor symptoms in Parkinson’s.

How does Parkinson disease affect the organ system?

Parkinson’s impacts ​multiple organ systems​, not just the brain. It can disrupt the gastrointestinal, urinary, cardiovascular, and respiratory systems due to autonomic nervous system involvement. This can lead to ​constipation, low blood pressure, bladder dysfunction, and even swallowing difficulties​. A comprehensive review from Nature Reviews Neurology highlights the broad systemic effects of Parkinson’s disease.

Does Parkinson's affect the kidneys?

Yes, emerging studies suggest that ​renal health and Parkinson’s disease are interconnected​. For example, a 2023 study reported the presence of ​α-synuclein aggregates in the kidneys​, indicating that pathological changes may originate in or involve renal tissues. Moreover, chronic kidney disease may exacerbate Parkinsonian symptoms through impaired toxin clearance and neurotransmitter imbalance.

How does Parkinson’s disease affect people's lives?

Parkinson’s disease significantly alters daily life by impacting ​mobility, speech, mood, sleep, digestion, and bladder function​. These symptoms can lead to social withdrawal, emotional distress, and increased caregiver burden. The Parkinson’s Foundation offers resources and strategies to help patients and families manage the wide-ranging effects of the disease on quality of life.